Endocrinology Research Analysis
February’s endocrinology research spotlighted immunometabolic control of glucose with a thromboxane axis that enhances muscle glucose uptake, alongside translational advances that can immediately shape care. Pelacarsen achieved profound Lp(a) lowering and sharply reduced apheresis utilization in secondary prevention, while once‑weekly somapacitan proved non‑inferior to daily growth hormone in idiopathic short stature, reducing treatment burden. Foundational biology progressed with a human NKX2.2
Summary
February’s endocrinology research spotlighted immunometabolic control of glucose with a thromboxane axis that enhances muscle glucose uptake, alongside translational advances that can immediately shape care. Pelacarsen achieved profound Lp(a) lowering and sharply reduced apheresis utilization in secondary prevention, while once‑weekly somapacitan proved non‑inferior to daily growth hormone in idiopathic short stature, reducing treatment burden. Foundational biology progressed with a human NKX2.2–CLEC16A/endosomal pathway model that enables pharmacologic rescue in autoimmune‑like T1D. Tissue‑specific nutrient handling emerged as a therapeutic entry point via druggable intestinal aPKC/GLUT1‑mediated glucose excretion.
Selected Articles
1. Thromboxane signalling links immune activation to enhanced glucose uptake in skeletal muscle.
A translational study shows that macrophage COX-2–driven thromboxane production with exercise enhances muscle glucose uptake via TBXA2R signalling, improving glycogen synthesis and glucose tolerance with efficacy preserved in obesity.
Impact: Reveals a druggable immunometabolic axis that acutely augments insulin-independent glucose disposal in skeletal muscle, opening a new therapeutic avenue for insulin-resistant states.
Clinical Implications: Targeting TBXA2R signalling could augment skeletal muscle glucose uptake and glycemic control; early-phase trials should assess safety, dose–response, and efficacy in insulin-resistant populations.
Key Findings
- Acute exercise increased plasma TXB2 and induced COX-2 (PTGS2) in muscle-resident monocytes/macrophages.
- Thromboxane receptor agonism rapidly increased muscle glucose uptake (up to 2.5×) and glycogen synthesis (~430%).
- Improved whole-body glucose tolerance was observed in vivo, including in diet-induced obese mice.
2. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.
A 52-week randomized, placebo-controlled study showed pelacarsen reduced normalized apheresis session rates and lowered Lp(a) by 72% in patients with established CVD and elevated Lp(a), with similar overall safety.
Impact: Demonstrates that Lp(a)-targeted antisense therapy can substantially reduce invasive apheresis utilization while achieving profound Lp(a) lowering in secondary prevention.
Clinical Implications: Pelacarsen may allow selected patients with very high Lp(a) to reduce or avoid routine apheresis; clinicians should consider trial referral and anticipate pending outcome data for effects on MACE.
Key Findings
- Normalized apheresis session rate was markedly lower with pelacarsen vs placebo (OR 0.006).
- Placebo-adjusted Lp(a) reduction at week 52 was −72% (95% CI −79% to −61%).
- Safety profile was similar aside from mild injection-site reactions.
3. Somapacitan in children with idiopathic short stature: a randomised controlled phase 3 study.
In prepubertal children with idiopathic short stature, once-weekly somapacitan was non-inferior to daily GH for height velocity over 52 weeks and reduced patient-reported treatment burden with similar safety.
Impact: Validates a long-acting GH regimen that can maintain efficacy while improving adherence and quality of life in pediatric endocrinology.
Clinical Implications: Somapacitan offers a practical alternative to daily GH for idiopathic short stature; continued surveillance for long-term metabolic safety is warranted.
Key Findings
- Height velocity at 52 weeks: 10.2 vs 10.6 cm/year (ETD −0.3 cm/year), confirming non-inferiority.
- Adverse event profiles were similar between groups.
- Patient-reported treatment burden favored once-weekly dosing.
4. Single-cell multi-omic analyses highlight the essential role of NKX2.2-CLEC16A/endosomal pathway for human pancreatic differentiation and function.
A human stem cell platform mapped endocrine lineage programs and identified an essential NKX2.2–CLEC16A/endosomal axis; CLEC16A knockout generated an autoimmune-like T1D model enabling discovery of pharmacologic rescuers.
Impact: Provides an intervention-ready human model and mechanistic blueprint to preserve or restore beta-cell differentiation/function in autoimmune diabetes.
Clinical Implications: Enables target discovery and early translational testing of agents that rescue CLEC16A-related defects and support beta-cell preservation.
Key Findings
- Single-cell transcriptome and chromatin dynamics define regulatory networks for endocrine bifurcation.
- An essential NKX2.2–CLEC16A/endosomal pathway is required for human pancreatic endocrine differentiation.
- CLEC16A knockout creates an autoimmune-like human T1D model and identifies pharmacologic rescuers.
5. Atypical protein kinase C activation drives intestinal glucose excretion in diabetes mellitus.
Preclinical work demonstrates that intestinal aPKC activation promotes GLUT1-mediated uptake of circulating glucose and luminal excretion, nominating a druggable pathway for glucose lowering and potential weight loss.
Impact: Defines a previously unrecognized intestinal route for systemic glucose disposal distinct from renal SGLT2 inhibition or bariatric surgery.
Clinical Implications: If translated, aPKC/GLUT1 modulators could represent a new class of glucose-lowering and weight-loss agents; first-in-human safety and dose–response studies are prioritized.
Key Findings
- aPKC activation recreates transcriptional signatures of intestinal glucose excretion.
- Facilitates GLUT1-mediated intestinal uptake of serum glucose and luminal excretion without proliferative signaling.
- Pharmacologic and genetic activation increased intestinal glucose excretion in vivo.